Shots: The P-III SOLAR-1 trial assessed BYL719 (300 mg, qd) + fulvestrant (500 mg) vs PBO (fulvestrant) in 572 postmenopausal women in ratio (1:1) with PIK3CA-mutated HR+/HER2- advanced or metastatic […]readmore
Tags : BYL719
Shots: In a global P-III combination of BYL719 + fulvestrant improved PFS vs fulvestrant in postmenopausal women and men with (HR+/HER2-) PIK3CA-mutant Breast Cancer that progressed on aromatase inh. ± […]readmore